| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endothelial Cells | 41 | 2022 | 324 | 10.510 |
Why?
|
| Mechanotransduction, Cellular | 32 | 2021 | 59 | 9.840 |
Why?
|
| Glycocalyx | 36 | 2021 | 37 | 9.570 |
Why?
|
| Endothelium, Vascular | 48 | 2021 | 261 | 7.620 |
Why?
|
| Models, Cardiovascular | 66 | 2016 | 97 | 7.500 |
Why?
|
| Stress, Mechanical | 73 | 2021 | 162 | 6.100 |
Why?
|
| Aorta | 30 | 2015 | 197 | 3.230 |
Why?
|
| Glypicans | 7 | 2021 | 8 | 3.090 |
Why?
|
| Atherosclerosis | 10 | 2022 | 164 | 3.050 |
Why?
|
| Muscle, Smooth, Vascular | 18 | 2015 | 142 | 2.920 |
Why?
|
| Heart Valve Prosthesis | 26 | 2005 | 45 | 2.830 |
Why?
|
| Nitric Oxide | 22 | 2021 | 381 | 2.810 |
Why?
|
| Myocytes, Smooth Muscle | 10 | 2015 | 92 | 2.750 |
Why?
|
| Arteries | 21 | 2020 | 81 | 2.460 |
Why?
|
| Heparan Sulfate Proteoglycans | 6 | 2019 | 12 | 2.380 |
Why?
|
| Cattle | 46 | 2016 | 505 | 2.290 |
Why?
|
| Cells, Cultured | 51 | 2021 | 1617 | 2.210 |
Why?
|
| Animals | 115 | 2022 | 16695 | 2.070 |
Why?
|
| Hemorheology | 23 | 2006 | 25 | 2.050 |
Why?
|
| Shear Strength | 15 | 2017 | 25 | 1.940 |
Why?
|
| Blood Flow Velocity | 36 | 2015 | 88 | 1.850 |
Why?
|
| Cell Movement | 7 | 2019 | 640 | 1.790 |
Why?
|
| Capillary Permeability | 13 | 2016 | 36 | 1.790 |
Why?
|
| Lipoproteins, LDL | 7 | 2016 | 66 | 1.720 |
Why?
|
| Models, Biological | 22 | 2018 | 711 | 1.680 |
Why?
|
| Heparitin Sulfate | 10 | 2019 | 23 | 1.640 |
Why?
|
| Pulsatile Flow | 19 | 2015 | 28 | 1.610 |
Why?
|
| Rheology | 28 | 2014 | 51 | 1.450 |
Why?
|
| Nitric Oxide Synthase Type III | 11 | 2021 | 74 | 1.390 |
Why?
|
| Syndecan-1 | 6 | 2019 | 9 | 1.370 |
Why?
|
| Computer Simulation | 14 | 2017 | 404 | 1.290 |
Why?
|
| Extracellular Fluid | 3 | 2019 | 15 | 1.260 |
Why?
|
| Heart-Assist Devices | 19 | 2000 | 37 | 1.240 |
Why?
|
| Water | 15 | 2023 | 314 | 1.230 |
Why?
|
| Glycosaminoglycans | 6 | 2018 | 24 | 1.190 |
Why?
|
| Vascular Diseases | 2 | 2021 | 33 | 1.170 |
Why?
|
| Lysophospholipids | 6 | 2018 | 19 | 1.140 |
Why?
|
| Rats | 31 | 2021 | 3701 | 1.120 |
Why?
|
| Hemodynamics | 16 | 2016 | 101 | 1.080 |
Why?
|
| Matrix Metalloproteinase 1 | 4 | 2015 | 26 | 1.010 |
Why?
|
| Mitral Valve | 13 | 2005 | 37 | 0.990 |
Why?
|
| Biological Transport | 18 | 2018 | 201 | 0.980 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 3 | 2011 | 103 | 0.970 |
Why?
|
| Gene Expression Regulation | 5 | 2019 | 1066 | 0.970 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2011 | 100 | 0.960 |
Why?
|
| Laser-Doppler Flowmetry | 13 | 2005 | 19 | 0.960 |
Why?
|
| Aorta, Thoracic | 10 | 2016 | 31 | 0.950 |
Why?
|
| Sphingosine | 5 | 2018 | 22 | 0.910 |
Why?
|
| Endothelium | 3 | 2016 | 28 | 0.910 |
Why?
|
| Coronary Vessels | 7 | 2016 | 92 | 0.910 |
Why?
|
| Heart, Artificial | 9 | 2004 | 11 | 0.890 |
Why?
|
| Humans | 91 | 2022 | 42163 | 0.880 |
Why?
|
| Blood Pressure | 20 | 2013 | 662 | 0.860 |
Why?
|
| Fibroblasts | 4 | 2015 | 278 | 0.830 |
Why?
|
| Retinal Vessels | 5 | 2011 | 29 | 0.830 |
Why?
|
| Integrins | 3 | 2019 | 54 | 0.830 |
Why?
|
| Epoprostenol | 5 | 2016 | 28 | 0.800 |
Why?
|
| Stress, Physiological | 4 | 2017 | 170 | 0.770 |
Why?
|
| Endothelin-1 | 4 | 2007 | 57 | 0.760 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 233 | 0.750 |
Why?
|
| Astrocytes | 2 | 2022 | 244 | 0.740 |
Why?
|
| Albumins | 6 | 2012 | 32 | 0.710 |
Why?
|
| Apoptosis | 6 | 2016 | 1541 | 0.680 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2011 | 51 | 0.650 |
Why?
|
| Membrane Microdomains | 3 | 2018 | 53 | 0.650 |
Why?
|
| Mice | 13 | 2022 | 6490 | 0.650 |
Why?
|
| Cell Membrane Permeability | 7 | 2018 | 57 | 0.640 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2019 | 48 | 0.630 |
Why?
|
| Gene Expression | 3 | 2022 | 692 | 0.630 |
Why?
|
| Syndecan-4 | 1 | 2019 | 4 | 0.630 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 77 | 0.620 |
Why?
|
| Pressure | 17 | 2010 | 49 | 0.620 |
Why?
|
| Calcium Signaling | 3 | 2005 | 108 | 0.610 |
Why?
|
| Cell Communication | 3 | 2017 | 110 | 0.610 |
Why?
|
| Electroosmosis | 1 | 2018 | 1 | 0.580 |
Why?
|
| Cyclooxygenase 2 | 2 | 2016 | 106 | 0.550 |
Why?
|
| Regional Blood Flow | 15 | 2020 | 52 | 0.530 |
Why?
|
| Cytoskeleton | 4 | 2014 | 111 | 0.530 |
Why?
|
| Prosthesis Design | 15 | 2005 | 48 | 0.520 |
Why?
|
| Finite Element Analysis | 5 | 2020 | 16 | 0.520 |
Why?
|
| Nitric Oxide Synthase | 7 | 2013 | 134 | 0.520 |
Why?
|
| Transcription Factor RelA | 1 | 2016 | 41 | 0.510 |
Why?
|
| Blood-Retinal Barrier | 5 | 2011 | 11 | 0.510 |
Why?
|
| Embolism, Air | 3 | 2002 | 4 | 0.510 |
Why?
|
| Indoles | 4 | 2002 | 178 | 0.490 |
Why?
|
| Intercellular Junctions | 4 | 2010 | 18 | 0.490 |
Why?
|
| Carbazoles | 3 | 2000 | 46 | 0.490 |
Why?
|
| Permeability | 9 | 2011 | 66 | 0.460 |
Why?
|
| Proteoglycans | 4 | 2018 | 49 | 0.460 |
Why?
|
| Hemolysis | 11 | 2000 | 59 | 0.460 |
Why?
|
| Matrix Metalloproteinase 13 | 2 | 2013 | 5 | 0.450 |
Why?
|
| Microcirculation | 5 | 2014 | 40 | 0.450 |
Why?
|
| Membrane Proteins | 7 | 2011 | 548 | 0.440 |
Why?
|
| Collagen | 4 | 2015 | 178 | 0.440 |
Why?
|
| Cell Line | 7 | 2018 | 1416 | 0.440 |
Why?
|
| Rats, Sprague-Dawley | 16 | 2016 | 1737 | 0.430 |
Why?
|
| Time Factors | 12 | 2016 | 1848 | 0.430 |
Why?
|
| Elastic Tissue | 3 | 2004 | 9 | 0.430 |
Why?
|
| Diabetic Angiopathies | 1 | 2013 | 26 | 0.420 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 729 | 0.410 |
Why?
|
| Membrane Fluidity | 1 | 2013 | 11 | 0.410 |
Why?
|
| Gels | 4 | 2011 | 43 | 0.410 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2011 | 180 | 0.400 |
Why?
|
| Mitral Valve Insufficiency | 4 | 2003 | 22 | 0.400 |
Why?
|
| Cell Membrane | 4 | 2014 | 400 | 0.400 |
Why?
|
| Cell Adhesion | 4 | 2017 | 237 | 0.400 |
Why?
|
| Hyaluronic Acid | 4 | 2017 | 36 | 0.400 |
Why?
|
| Aorta, Abdominal | 3 | 1998 | 17 | 0.390 |
Why?
|
| Chondroitin Sulfates | 4 | 2015 | 11 | 0.390 |
Why?
|
| Collagen Type I | 2 | 2009 | 35 | 0.390 |
Why?
|
| Endothelial Growth Factors | 4 | 2000 | 9 | 0.380 |
Why?
|
| Lymphokines | 4 | 2000 | 17 | 0.380 |
Why?
|
| Extracellular Matrix | 2 | 2012 | 129 | 0.370 |
Why?
|
| Algorithms | 6 | 2006 | 508 | 0.370 |
Why?
|
| RNA, Small Interfering | 4 | 2021 | 436 | 0.360 |
Why?
|
| Polysaccharide-Lyases | 5 | 2015 | 10 | 0.350 |
Why?
|
| Body Fluids | 2 | 2010 | 18 | 0.350 |
Why?
|
| Arteriosclerosis | 3 | 2003 | 42 | 0.350 |
Why?
|
| Oxygen | 3 | 2020 | 217 | 0.350 |
Why?
|
| Embryonic Stem Cells | 1 | 2011 | 55 | 0.350 |
Why?
|
| Capillaries | 4 | 2012 | 27 | 0.350 |
Why?
|
| Cryopreservation | 1 | 2011 | 33 | 0.350 |
Why?
|
| Arterioles | 3 | 2015 | 19 | 0.340 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2011 | 21 | 0.340 |
Why?
|
| Chemotaxis | 2 | 2011 | 66 | 0.340 |
Why?
|
| Body Water | 4 | 2011 | 25 | 0.340 |
Why?
|
| Vasa Vasorum | 2 | 2020 | 3 | 0.330 |
Why?
|
| Glioma | 1 | 2011 | 92 | 0.330 |
Why?
|
| Antigens, CD | 3 | 2016 | 122 | 0.330 |
Why?
|
| Hyperglycemia | 1 | 2011 | 60 | 0.330 |
Why?
|
| Electromagnetic Fields | 1 | 2010 | 9 | 0.330 |
Why?
|
| Enzyme Inhibitors | 9 | 2005 | 457 | 0.320 |
Why?
|
| Deep Brain Stimulation | 1 | 2010 | 17 | 0.320 |
Why?
|
| Mitosis | 1 | 2010 | 112 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2009 | 24 | 0.310 |
Why?
|
| Microscopy, Atomic Force | 2 | 2021 | 62 | 0.310 |
Why?
|
| omega-N-Methylarginine | 6 | 2015 | 8 | 0.310 |
Why?
|
| Phosphorylation | 4 | 2021 | 973 | 0.300 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 73 | 0.300 |
Why?
|
| Numerical Analysis, Computer-Assisted | 3 | 2000 | 11 | 0.300 |
Why?
|
| Diffusion | 7 | 2015 | 63 | 0.300 |
Why?
|
| Elasticity | 10 | 2007 | 50 | 0.290 |
Why?
|
| RNA Interference | 4 | 2016 | 246 | 0.290 |
Why?
|
| Oxygen Consumption | 2 | 2006 | 111 | 0.290 |
Why?
|
| Male | 22 | 2022 | 22779 | 0.280 |
Why?
|
| Umbilical Veins | 2 | 2005 | 18 | 0.280 |
Why?
|
| Cell Culture Techniques | 4 | 2013 | 151 | 0.280 |
Why?
|
| Cell Proliferation | 2 | 2021 | 1420 | 0.280 |
Why?
|
| Cell Line, Tumor | 4 | 2019 | 2598 | 0.280 |
Why?
|
| Cholesterol | 2 | 2016 | 230 | 0.280 |
Why?
|
| Mice, Knockout | 2 | 2021 | 1010 | 0.280 |
Why?
|
| Up-Regulation | 4 | 2016 | 534 | 0.280 |
Why?
|
| Blood Circulation | 2 | 2003 | 3 | 0.280 |
Why?
|
| Hypertension | 3 | 2015 | 823 | 0.270 |
Why?
|
| Mesentery | 2 | 2016 | 9 | 0.270 |
Why?
|
| Linoleic Acids, Conjugated | 1 | 2007 | 3 | 0.270 |
Why?
|
| Muscle Contraction | 2 | 2004 | 67 | 0.260 |
Why?
|
| Transport Vesicles | 1 | 2007 | 22 | 0.260 |
Why?
|
| Tight Junctions | 5 | 2010 | 27 | 0.260 |
Why?
|
| Carotid Sinus | 1 | 2006 | 1 | 0.260 |
Why?
|
| Serum Albumin, Bovine | 2 | 2004 | 49 | 0.250 |
Why?
|
| Materials Testing | 4 | 2005 | 99 | 0.250 |
Why?
|
| Blood Vessel Prosthesis | 2 | 1996 | 5 | 0.250 |
Why?
|
| Adherens Junctions | 2 | 2017 | 11 | 0.250 |
Why?
|
| Biomedical Engineering | 6 | 2001 | 12 | 0.250 |
Why?
|
| Intracellular Fluid | 1 | 2005 | 27 | 0.240 |
Why?
|
| Vascular Resistance | 4 | 2020 | 37 | 0.240 |
Why?
|
| Carotid Artery, Internal | 1 | 2005 | 8 | 0.240 |
Why?
|
| Carotid Artery, External | 1 | 2005 | 5 | 0.240 |
Why?
|
| Glycoproteins | 3 | 2016 | 127 | 0.230 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 1554 | 0.230 |
Why?
|
| Prosthesis Failure | 7 | 2003 | 18 | 0.230 |
Why?
|
| Serum | 1 | 2004 | 17 | 0.230 |
Why?
|
| Blood Vessels | 2 | 2012 | 36 | 0.230 |
Why?
|
| Phenotype | 3 | 2016 | 774 | 0.220 |
Why?
|
| Adenosine Triphosphate | 2 | 2004 | 205 | 0.220 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2016 | 95 | 0.220 |
Why?
|
| Coronary Circulation | 3 | 2000 | 29 | 0.220 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 43 | 0.220 |
Why?
|
| Actins | 3 | 2014 | 162 | 0.220 |
Why?
|
| Adipose Tissue | 2 | 2017 | 180 | 0.220 |
Why?
|
| Thrombosis | 6 | 2004 | 81 | 0.210 |
Why?
|
| Homeostasis | 1 | 2005 | 193 | 0.210 |
Why?
|
| Protein Binding | 2 | 2021 | 1076 | 0.210 |
Why?
|
| Membranes, Artificial | 1 | 2003 | 33 | 0.210 |
Why?
|
| Tissue Distribution | 4 | 2013 | 230 | 0.210 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2004 | 167 | 0.210 |
Why?
|
| Enzyme Activation | 3 | 2014 | 462 | 0.210 |
Why?
|
| Carotid Arteries | 3 | 2015 | 35 | 0.210 |
Why?
|
| Water-Electrolyte Balance | 1 | 2003 | 17 | 0.210 |
Why?
|
| Equipment Failure Analysis | 4 | 2004 | 45 | 0.210 |
Why?
|
| Dextrans | 5 | 2011 | 28 | 0.200 |
Why?
|
| Cadherins | 2 | 2014 | 102 | 0.200 |
Why?
|
| Models, Structural | 5 | 2005 | 12 | 0.200 |
Why?
|
| Blood Viscosity | 6 | 1994 | 9 | 0.200 |
Why?
|
| Fluorescein | 3 | 2017 | 18 | 0.200 |
Why?
|
| Neovascularization, Pathologic | 2 | 2020 | 137 | 0.200 |
Why?
|
| Blood Substitutes | 2 | 1996 | 5 | 0.200 |
Why?
|
| Thrombin | 3 | 2016 | 28 | 0.200 |
Why?
|
| Tunica Intima | 4 | 2007 | 21 | 0.190 |
Why?
|
| Biological Transport, Active | 3 | 2011 | 27 | 0.190 |
Why?
|
| Inflammation | 3 | 2022 | 729 | 0.190 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 683 | 0.190 |
Why?
|
| Reproducibility of Results | 7 | 2016 | 1058 | 0.190 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2022 | 81 | 0.190 |
Why?
|
| Resins, Synthetic | 2 | 2005 | 2 | 0.180 |
Why?
|
| Aortic Valve | 5 | 1998 | 38 | 0.180 |
Why?
|
| Mathematics | 8 | 2000 | 57 | 0.180 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 188 | 0.180 |
Why?
|
| Cell Division | 3 | 2009 | 314 | 0.180 |
Why?
|
| Compliance | 5 | 2000 | 14 | 0.180 |
Why?
|
| Neuronal Plasticity | 1 | 2022 | 126 | 0.180 |
Why?
|
| Macromolecular Substances | 4 | 2004 | 95 | 0.180 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2001 | 20 | 0.170 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 2 | 2012 | 2 | 0.170 |
Why?
|
| Hyaluronoglucosaminidase | 2 | 2012 | 20 | 0.170 |
Why?
|
| Lipoproteins | 2 | 2016 | 68 | 0.170 |
Why?
|
| Cyclic GMP | 4 | 2002 | 55 | 0.170 |
Why?
|
| Glucose | 2 | 2013 | 242 | 0.170 |
Why?
|
| Hydrostatic Pressure | 5 | 2010 | 9 | 0.170 |
Why?
|
| Signal Processing, Computer-Assisted | 5 | 2005 | 67 | 0.170 |
Why?
|
| Microscopy, Video | 3 | 2005 | 12 | 0.160 |
Why?
|
| Erythrocytes | 3 | 1997 | 126 | 0.160 |
Why?
|
| Stents | 1 | 2020 | 66 | 0.160 |
Why?
|
| Rats, Wistar | 3 | 2005 | 282 | 0.160 |
Why?
|
| Signal Transduction | 4 | 2016 | 2111 | 0.160 |
Why?
|
| Glycerol | 3 | 2000 | 34 | 0.160 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 138 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 4 | 2022 | 1804 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2012 | 170 | 0.160 |
Why?
|
| Blotting, Western | 3 | 2011 | 884 | 0.160 |
Why?
|
| Models, Theoretical | 3 | 2014 | 230 | 0.150 |
Why?
|
| Surface Properties | 4 | 2006 | 157 | 0.150 |
Why?
|
| Hematocrit | 4 | 1994 | 25 | 0.150 |
Why?
|
| Rabbits | 5 | 2006 | 292 | 0.150 |
Why?
|
| Tunica Media | 2 | 2000 | 14 | 0.150 |
Why?
|
| Anastomosis, Surgical | 2 | 1996 | 27 | 0.150 |
Why?
|
| Tissue Engineering | 1 | 2019 | 72 | 0.150 |
Why?
|
| Anisotropy | 3 | 2020 | 33 | 0.150 |
Why?
|
| Cardiac Output | 3 | 1997 | 24 | 0.150 |
Why?
|
| Microscopy | 2 | 2019 | 33 | 0.140 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2019 | 98 | 0.140 |
Why?
|
| Blood-Brain Barrier | 2 | 2010 | 167 | 0.140 |
Why?
|
| Microvessels | 2 | 2016 | 31 | 0.140 |
Why?
|
| Osmotic Pressure | 3 | 2015 | 22 | 0.140 |
Why?
|
| Cardiovascular Agents | 1 | 1998 | 24 | 0.140 |
Why?
|
| Age Factors | 1 | 2021 | 1139 | 0.140 |
Why?
|
| Carbon Dioxide | 3 | 2005 | 86 | 0.140 |
Why?
|
| Intracellular Space | 1 | 2017 | 37 | 0.140 |
Why?
|
| Indicators and Reagents | 1 | 2017 | 59 | 0.130 |
Why?
|
| Blood Proteins | 1 | 2018 | 75 | 0.130 |
Why?
|
| Dogs | 5 | 2002 | 201 | 0.130 |
Why?
|
| NF-kappa B | 2 | 2022 | 355 | 0.130 |
Why?
|
| Cilia | 1 | 2016 | 29 | 0.130 |
Why?
|
| Swine | 5 | 1999 | 205 | 0.130 |
Why?
|
| Sulfotransferases | 1 | 2016 | 9 | 0.130 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2016 | 60 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factors | 4 | 2000 | 10 | 0.130 |
Why?
|
| Factor Xa | 1 | 2016 | 4 | 0.130 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 22 | 0.130 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 3 | 2000 | 9 | 0.130 |
Why?
|
| Aminoquinolines | 3 | 2000 | 17 | 0.130 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 54 | 0.130 |
Why?
|
| Lasers | 1 | 1996 | 57 | 0.130 |
Why?
|
| Guanylate Cyclase | 3 | 2000 | 21 | 0.130 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 105 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 649 | 0.130 |
Why?
|
| Spheroids, Cellular | 1 | 2016 | 37 | 0.130 |
Why?
|
| Down-Regulation | 2 | 2011 | 452 | 0.130 |
Why?
|
| Blood Coagulation | 1 | 2016 | 29 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2016 | 84 | 0.120 |
Why?
|
| Dinoprostone | 1 | 1996 | 69 | 0.120 |
Why?
|
| Video Recording | 2 | 1999 | 40 | 0.120 |
Why?
|
| Mice, SCID | 1 | 2016 | 158 | 0.120 |
Why?
|
| Equipment Design | 7 | 2004 | 143 | 0.120 |
Why?
|
| Coculture Techniques | 2 | 2013 | 105 | 0.120 |
Why?
|
| Biological Assay | 1 | 2016 | 63 | 0.120 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2007 | 30 | 0.120 |
Why?
|
| Alkaloids | 3 | 2000 | 46 | 0.120 |
Why?
|
| Cell Differentiation | 2 | 2011 | 633 | 0.120 |
Why?
|
| Blood Platelets | 1 | 2016 | 80 | 0.120 |
Why?
|
| Polysaccharides, Bacterial | 2 | 1993 | 17 | 0.120 |
Why?
|
| Exocytosis | 1 | 2015 | 49 | 0.120 |
Why?
|
| Physical Stimulation | 2 | 2006 | 27 | 0.120 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 928 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 506 | 0.120 |
Why?
|
| NG-Nitroarginine Methyl Ester | 2 | 2005 | 36 | 0.120 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2016 | 160 | 0.110 |
Why?
|
| Aquaporin 1 | 1 | 2015 | 8 | 0.110 |
Why?
|
| Electric Conductivity | 2 | 2010 | 55 | 0.110 |
Why?
|
| Sepsis | 1 | 2015 | 90 | 0.110 |
Why?
|
| Vasoconstrictor Agents | 1 | 1994 | 42 | 0.110 |
Why?
|
| Focal Adhesions | 1 | 2014 | 16 | 0.110 |
Why?
|
| Lipids | 1 | 2016 | 256 | 0.110 |
Why?
|
| Blood Cells | 1 | 2014 | 8 | 0.110 |
Why?
|
| Vasodilator Agents | 1 | 1994 | 55 | 0.110 |
Why?
|
| Caveolae | 1 | 2014 | 10 | 0.110 |
Why?
|
| Ventricular Pressure | 3 | 2002 | 8 | 0.110 |
Why?
|
| Viscosity | 4 | 2000 | 46 | 0.110 |
Why?
|
| Phosphoproteins | 4 | 2010 | 201 | 0.110 |
Why?
|
| Vascular Patency | 1 | 1994 | 3 | 0.110 |
Why?
|
| Sucrose | 1 | 1994 | 33 | 0.110 |
Why?
|
| G(M1) Ganglioside | 1 | 2014 | 13 | 0.110 |
Why?
|
| Nitrates | 3 | 2010 | 63 | 0.110 |
Why?
|
| Brain | 4 | 2023 | 1452 | 0.110 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2015 | 16 | 0.110 |
Why?
|
| Cell Shape | 1 | 2014 | 42 | 0.110 |
Why?
|
| Integrin alpha3 | 1 | 2013 | 1 | 0.110 |
Why?
|
| Chlorofluorocarbons, Methane | 2 | 1990 | 3 | 0.110 |
Why?
|
| Videotape Recording | 3 | 2000 | 29 | 0.110 |
Why?
|
| Adaptation, Physiological | 2 | 2005 | 135 | 0.110 |
Why?
|
| Rhodamines | 2 | 2011 | 23 | 0.110 |
Why?
|
| Perfusion | 4 | 2012 | 39 | 0.100 |
Why?
|
| Caveolin 1 | 1 | 2014 | 33 | 0.100 |
Why?
|
| Gelatin | 1 | 2013 | 16 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 2 | 2015 | 214 | 0.100 |
Why?
|
| Phospholipids | 1 | 2014 | 69 | 0.100 |
Why?
|
| Peptides | 1 | 2016 | 357 | 0.100 |
Why?
|
| Calcium | 3 | 2004 | 487 | 0.100 |
Why?
|
| Blood Physiological Phenomena | 2 | 1991 | 6 | 0.100 |
Why?
|
| Matrix Metalloproteinases | 1 | 2013 | 49 | 0.100 |
Why?
|
| Sensitivity and Specificity | 4 | 2003 | 602 | 0.100 |
Why?
|
| Plasma Substitutes | 1 | 1993 | 2 | 0.100 |
Why?
|
| Models, Chemical | 2 | 2007 | 205 | 0.100 |
Why?
|
| Assisted Circulation | 3 | 1988 | 4 | 0.100 |
Why?
|
| Ultrasonography | 3 | 2004 | 132 | 0.100 |
Why?
|
| Electroporation | 2 | 2010 | 21 | 0.100 |
Why?
|
| Osmosis | 2 | 2004 | 9 | 0.100 |
Why?
|
| Software | 1 | 2014 | 234 | 0.100 |
Why?
|
| Hyperplasia | 2 | 2007 | 39 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 84 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2009 | 438 | 0.090 |
Why?
|
| Electric Impedance | 3 | 2010 | 28 | 0.090 |
Why?
|
| Adsorption | 1 | 2012 | 74 | 0.090 |
Why?
|
| Elastic Modulus | 1 | 2012 | 20 | 0.090 |
Why?
|
| Bradykinin | 2 | 2003 | 23 | 0.090 |
Why?
|
| Histocytochemistry | 1 | 2011 | 47 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 254 | 0.090 |
Why?
|
| Extracellular Space | 2 | 2002 | 36 | 0.090 |
Why?
|
| Nitrites | 2 | 2002 | 54 | 0.090 |
Why?
|
| Chemotactic Factors | 1 | 2011 | 8 | 0.090 |
Why?
|
| Freeze Substitution | 1 | 2011 | 1 | 0.090 |
Why?
|
| Erythrocyte Deformability | 1 | 1991 | 2 | 0.090 |
Why?
|
| Fluorescence | 1 | 2011 | 113 | 0.090 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 138 | 0.090 |
Why?
|
| Platelet Activation | 1 | 1990 | 6 | 0.080 |
Why?
|
| Binding Sites | 1 | 2012 | 670 | 0.080 |
Why?
|
| Cell Survival | 2 | 2011 | 934 | 0.080 |
Why?
|
| Diet | 1 | 2016 | 810 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2010 | 64 | 0.080 |
Why?
|
| Penicillamine | 2 | 2000 | 5 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 284 | 0.080 |
Why?
|
| Microscopy, Confocal | 4 | 2015 | 223 | 0.080 |
Why?
|
| Genes, fos | 1 | 2009 | 14 | 0.080 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2009 | 8 | 0.080 |
Why?
|
| Nitric Oxide Donors | 2 | 2000 | 41 | 0.080 |
Why?
|
| Electrodes | 1 | 2010 | 57 | 0.080 |
Why?
|
| Bucladesine | 3 | 2001 | 10 | 0.080 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2009 | 8 | 0.080 |
Why?
|
| Transcription Factor AP-1 | 1 | 2009 | 31 | 0.080 |
Why?
|
| Thromboembolism | 2 | 2003 | 20 | 0.080 |
Why?
|
| Flavonoids | 1 | 2010 | 94 | 0.080 |
Why?
|
| Cycloheximide | 1 | 2009 | 30 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 454 | 0.080 |
Why?
|
| Cell Separation | 1 | 2009 | 94 | 0.080 |
Why?
|
| Heparin Lyase | 1 | 2009 | 2 | 0.080 |
Why?
|
| Pronase | 1 | 2009 | 4 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2011 | 318 | 0.080 |
Why?
|
| Evaluation Studies as Topic | 3 | 1994 | 62 | 0.080 |
Why?
|
| Dipeptides | 1 | 2009 | 31 | 0.080 |
Why?
|
| Models, Anatomic | 2 | 2000 | 19 | 0.080 |
Why?
|
| Polymers | 1 | 2010 | 151 | 0.080 |
Why?
|
| Necrosis | 1 | 2009 | 54 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 53 | 0.080 |
Why?
|
| DNA Primers | 1 | 2009 | 295 | 0.080 |
Why?
|
| Gene Silencing | 1 | 2009 | 154 | 0.070 |
Why?
|
| Cell Death | 1 | 2010 | 277 | 0.070 |
Why?
|
| Serum Albumin | 3 | 2003 | 58 | 0.070 |
Why?
|
| Enzymes | 1 | 2008 | 34 | 0.070 |
Why?
|
| Filtration | 2 | 2004 | 17 | 0.070 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2008 | 33 | 0.070 |
Why?
|
| Sodium Chloride | 2 | 2000 | 54 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 933 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2004 | 57 | 0.070 |
Why?
|
| RNA | 1 | 2009 | 266 | 0.070 |
Why?
|
| Smooth Muscle Myosins | 1 | 2007 | 1 | 0.070 |
Why?
|
| Connective Tissue | 1 | 2007 | 7 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2007 | 9 | 0.070 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2007 | 7 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 379 | 0.070 |
Why?
|
| Myosin Heavy Chains | 1 | 2007 | 18 | 0.070 |
Why?
|
| PPAR gamma | 1 | 2007 | 55 | 0.060 |
Why?
|
| PPAR alpha | 1 | 2007 | 43 | 0.060 |
Why?
|
| Computational Biology | 1 | 2009 | 324 | 0.060 |
Why?
|
| Isoproterenol | 2 | 1998 | 38 | 0.060 |
Why?
|
| Biophysical Phenomena | 2 | 1996 | 22 | 0.060 |
Why?
|
| Biophysics | 2 | 1996 | 38 | 0.060 |
Why?
|
| Angiotensin II | 2 | 1998 | 103 | 0.060 |
Why?
|
| Blood Volume | 1 | 2005 | 6 | 0.060 |
Why?
|
| Xanthenes | 1 | 2005 | 12 | 0.060 |
Why?
|
| Acoustics | 1 | 2005 | 17 | 0.060 |
Why?
|
| Fluoresceins | 3 | 2015 | 29 | 0.060 |
Why?
|
| Fluorescein-5-isothiocyanate | 2 | 1997 | 25 | 0.060 |
Why?
|
| Flow Injection Analysis | 1 | 2004 | 2 | 0.060 |
Why?
|
| Neoplasms | 1 | 2016 | 1341 | 0.060 |
Why?
|
| Sonication | 1 | 2004 | 14 | 0.060 |
Why?
|
| Systole | 2 | 1998 | 67 | 0.060 |
Why?
|
| Muscle, Smooth | 1 | 2004 | 59 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 182 | 0.050 |
Why?
|
| Solvents | 1 | 2004 | 109 | 0.050 |
Why?
|
| Histamine | 1 | 2003 | 20 | 0.050 |
Why?
|
| Physics | 1 | 2023 | 2 | 0.050 |
Why?
|
| Blood Pressure Determination | 1 | 2003 | 53 | 0.050 |
Why?
|
| Solutions | 2 | 2002 | 65 | 0.050 |
Why?
|
| Head | 1 | 2023 | 28 | 0.050 |
Why?
|
| Biocompatible Materials | 2 | 2005 | 106 | 0.050 |
Why?
|
| Skin | 1 | 2004 | 185 | 0.050 |
Why?
|
| ADP Ribose Transferases | 1 | 2002 | 7 | 0.050 |
Why?
|
| Sulfates | 1 | 2022 | 26 | 0.050 |
Why?
|
| Botulinum Toxins | 1 | 2002 | 11 | 0.050 |
Why?
|
| Maleimides | 1 | 2002 | 12 | 0.050 |
Why?
|
| Respiration | 1 | 1982 | 56 | 0.050 |
Why?
|
| Acrylic Resins | 2 | 1994 | 12 | 0.050 |
Why?
|
| Female | 7 | 2022 | 24018 | 0.050 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2002 | 26 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 308 | 0.050 |
Why?
|
| Apolipoproteins E | 1 | 2022 | 137 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2002 | 135 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2002 | 158 | 0.040 |
Why?
|
| Coloring Agents | 2 | 1997 | 56 | 0.040 |
Why?
|
| Nonlinear Dynamics | 1 | 2001 | 35 | 0.040 |
Why?
|
| Prostaglandins E | 1 | 2000 | 4 | 0.040 |
Why?
|
| Sodium Iodide | 1 | 2000 | 4 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2000 | 11 | 0.040 |
Why?
|
| Risk Factors | 2 | 2000 | 3942 | 0.040 |
Why?
|
| Transfection | 2 | 2015 | 526 | 0.040 |
Why?
|
| Analog-Digital Conversion | 1 | 2000 | 2 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2000 | 158 | 0.040 |
Why?
|
| Retina | 2 | 2000 | 288 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2000 | 37 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2000 | 42 | 0.040 |
Why?
|
| Staurosporine | 1 | 2000 | 38 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2000 | 30 | 0.040 |
Why?
|
| Fiber Optic Technology | 2 | 1997 | 11 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2000 | 47 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2000 | 100 | 0.040 |
Why?
|
| Stochastic Processes | 1 | 2019 | 8 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2000 | 124 | 0.040 |
Why?
|
| Echocardiography, Doppler | 1 | 1999 | 41 | 0.040 |
Why?
|
| Transducers | 1 | 1998 | 14 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2000 | 159 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2000 | 164 | 0.040 |
Why?
|
| Diastole | 1 | 1998 | 47 | 0.030 |
Why?
|
| Adenosine-5'-(N-ethylcarboxamide) | 1 | 1997 | 2 | 0.030 |
Why?
|
| Hemoglobins | 2 | 1996 | 112 | 0.030 |
Why?
|
| Motion | 1 | 1997 | 30 | 0.030 |
Why?
|
| Adenosine | 1 | 1997 | 62 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1998 | 126 | 0.030 |
Why?
|
| Blood | 2 | 1994 | 37 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 1997 | 221 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2000 | 960 | 0.030 |
Why?
|
| Photochemistry | 1 | 1996 | 58 | 0.030 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1996 | 5 | 0.030 |
Why?
|
| Antithrombins | 1 | 2016 | 3 | 0.030 |
Why?
|
| Heparin | 1 | 2016 | 39 | 0.030 |
Why?
|
| Temperature | 1 | 1997 | 314 | 0.030 |
Why?
|
| Kinetics | 2 | 2015 | 698 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1996 | 17 | 0.030 |
Why?
|
| Hair | 1 | 2015 | 38 | 0.030 |
Why?
|
| Heart | 1 | 1997 | 181 | 0.030 |
Why?
|
| Graft Survival | 1 | 1996 | 47 | 0.030 |
Why?
|
| Reference Values | 1 | 1996 | 207 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 196 | 0.030 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 1995 | 14 | 0.030 |
Why?
|
| Lysosomes | 1 | 2015 | 88 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 173 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 279 | 0.030 |
Why?
|
| Physiology | 1 | 1995 | 17 | 0.030 |
Why?
|
| Nitroprusside | 1 | 1994 | 14 | 0.030 |
Why?
|
| Fourier Analysis | 1 | 1994 | 45 | 0.030 |
Why?
|
| Poloxalene | 1 | 1994 | 1 | 0.030 |
Why?
|
| Norepinephrine | 1 | 1994 | 110 | 0.030 |
Why?
|
| Venous Pressure | 1 | 1994 | 2 | 0.030 |
Why?
|
| Porosity | 1 | 1994 | 42 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 235 | 0.030 |
Why?
|
| Cell Size | 1 | 1994 | 46 | 0.030 |
Why?
|
| Hemoglobinometry | 1 | 1993 | 1 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 1994 | 101 | 0.030 |
Why?
|
| Heart Ventricles | 1 | 1994 | 123 | 0.020 |
Why?
|
| Heart Rate | 2 | 1991 | 261 | 0.020 |
Why?
|
| Child | 1 | 2000 | 3381 | 0.020 |
Why?
|
| Thiocyanates | 1 | 1991 | 7 | 0.020 |
Why?
|
| Erythrocyte Membrane | 1 | 1991 | 20 | 0.020 |
Why?
|
| Cricetinae | 1 | 1991 | 241 | 0.020 |
Why?
|
| Electronics, Medical | 1 | 1990 | 2 | 0.020 |
Why?
|
| Cations | 1 | 2010 | 49 | 0.020 |
Why?
|
| Electric Power Supplies | 1 | 1990 | 15 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2010 | 10 | 0.020 |
Why?
|
| Ultrasonics | 2 | 1987 | 15 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2008 | 39 | 0.020 |
Why?
|
| Cell Wall | 1 | 1988 | 55 | 0.020 |
Why?
|
| Polysaccharides | 1 | 1988 | 70 | 0.020 |
Why?
|
| Lung | 1 | 2010 | 484 | 0.020 |
Why?
|
| Partial Pressure | 1 | 2005 | 9 | 0.020 |
Why?
|
| Solubility | 1 | 2005 | 134 | 0.010 |
Why?
|
| Mechanics | 1 | 2005 | 3 | 0.010 |
Why?
|
| Photography | 1 | 2005 | 48 | 0.010 |
Why?
|
| DNA | 1 | 2008 | 594 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 2004 | 48 | 0.010 |
Why?
|
| Carbon | 1 | 2005 | 127 | 0.010 |
Why?
|
| Cytochalasin D | 1 | 2003 | 3 | 0.010 |
Why?
|
| Colchicine | 1 | 2003 | 15 | 0.010 |
Why?
|
| Adult | 1 | 2000 | 13458 | 0.010 |
Why?
|
| Oscillometry | 1 | 1983 | 9 | 0.010 |
Why?
|
| Particle Size | 1 | 2004 | 267 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 574 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 1982 | 47 | 0.010 |
Why?
|
| Thapsigargin | 1 | 2002 | 8 | 0.010 |
Why?
|
| Ryanodine | 1 | 2002 | 4 | 0.010 |
Why?
|
| Hydroquinones | 1 | 2001 | 10 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2001 | 139 | 0.010 |
Why?
|
| Plasma | 1 | 1996 | 38 | 0.010 |
Why?
|
| Aged | 1 | 1989 | 7982 | 0.010 |
Why?
|
| Receptors, Purinergic | 1 | 1992 | 6 | 0.010 |
Why?
|
| Pyrilamine | 1 | 1992 | 1 | 0.010 |
Why?
|
| Histamine H1 Antagonists | 1 | 1992 | 5 | 0.010 |
Why?
|
| Indicator Dilution Techniques | 1 | 1991 | 1 | 0.010 |
Why?
|
| Optical Fibers | 1 | 1991 | 8 | 0.010 |
Why?
|
| Complement Activation | 1 | 1991 | 14 | 0.010 |
Why?
|
| Calibration | 1 | 1988 | 62 | 0.000 |
Why?
|